An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Andrzej P. Kudelka, Rodger Winn, Creighton L. Edwards, G. Downey, Harvey Greenberg, S. R. Dakhil, Ralph S. Freedman, Salvatore LoCoco, J. Umbreit, James E. Delmore, Susan Arbuck, Evelyne Loyer, Patsy Gacrama, Rebecca Fueger, John J. Kavanagh

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

Original languageEnglish (US)
Pages (from-to)657-661
Number of pages5
JournalAnti-Cancer Drugs
Volume8
Issue number7
DOIs
StatePublished - Oct 6 1997
Externally publishedYes

Fingerprint

Squamous Cell Neoplasms
Paclitaxel
Uterine Cervical Neoplasms
Granulocyte Colony-Stimulating Factor
Agranulocytosis
Premedication
Appointments and Schedules
Survival

Keywords

  • Cervix cancer
  • Granulocyte colony stimulating factor
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Kudelka, A. P., Winn, R., Edwards, C. L., Downey, G., Greenberg, H., Dakhil, S. R., ... Kavanagh, J. J. (1997). An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anti-Cancer Drugs, 8(7), 657-661. https://doi.org/10.1097/00001813-199708000-00002

An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. / Kudelka, Andrzej P.; Winn, Rodger; Edwards, Creighton L.; Downey, G.; Greenberg, Harvey; Dakhil, S. R.; Freedman, Ralph S.; LoCoco, Salvatore; Umbreit, J.; Delmore, James E.; Arbuck, Susan; Loyer, Evelyne; Gacrama, Patsy; Fueger, Rebecca; Kavanagh, John J.

In: Anti-Cancer Drugs, Vol. 8, No. 7, 06.10.1997, p. 657-661.

Research output: Contribution to journalArticle

Kudelka, AP, Winn, R, Edwards, CL, Downey, G, Greenberg, H, Dakhil, SR, Freedman, RS, LoCoco, S, Umbreit, J, Delmore, JE, Arbuck, S, Loyer, E, Gacrama, P, Fueger, R & Kavanagh, JJ 1997, 'An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix', Anti-Cancer Drugs, vol. 8, no. 7, pp. 657-661. https://doi.org/10.1097/00001813-199708000-00002
Kudelka, Andrzej P. ; Winn, Rodger ; Edwards, Creighton L. ; Downey, G. ; Greenberg, Harvey ; Dakhil, S. R. ; Freedman, Ralph S. ; LoCoco, Salvatore ; Umbreit, J. ; Delmore, James E. ; Arbuck, Susan ; Loyer, Evelyne ; Gacrama, Patsy ; Fueger, Rebecca ; Kavanagh, John J. / An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. In: Anti-Cancer Drugs. 1997 ; Vol. 8, No. 7. pp. 657-661.
@article{5dd80595f90640f7afef18765b047420,
title = "An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix",
abstract = "Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25{\%}, 95{\%} CI 8-38{\%}). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.",
keywords = "Cervix cancer, Granulocyte colony stimulating factor, Paclitaxel",
author = "Kudelka, {Andrzej P.} and Rodger Winn and Edwards, {Creighton L.} and G. Downey and Harvey Greenberg and Dakhil, {S. R.} and Freedman, {Ralph S.} and Salvatore LoCoco and J. Umbreit and Delmore, {James E.} and Susan Arbuck and Evelyne Loyer and Patsy Gacrama and Rebecca Fueger and Kavanagh, {John J.}",
year = "1997",
month = "10",
day = "6",
doi = "10.1097/00001813-199708000-00002",
language = "English (US)",
volume = "8",
pages = "657--661",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

AU - Kudelka, Andrzej P.

AU - Winn, Rodger

AU - Edwards, Creighton L.

AU - Downey, G.

AU - Greenberg, Harvey

AU - Dakhil, S. R.

AU - Freedman, Ralph S.

AU - LoCoco, Salvatore

AU - Umbreit, J.

AU - Delmore, James E.

AU - Arbuck, Susan

AU - Loyer, Evelyne

AU - Gacrama, Patsy

AU - Fueger, Rebecca

AU - Kavanagh, John J.

PY - 1997/10/6

Y1 - 1997/10/6

N2 - Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

AB - Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

KW - Cervix cancer

KW - Granulocyte colony stimulating factor

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=9844223395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9844223395&partnerID=8YFLogxK

U2 - 10.1097/00001813-199708000-00002

DO - 10.1097/00001813-199708000-00002

M3 - Article

C2 - 9311440

AN - SCOPUS:9844223395

VL - 8

SP - 657

EP - 661

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 7

ER -